secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001654954-24-009988
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics Raises $100M in Oversubscribed Private Placement Led by BVF Partners
--------------------------------------------------------------------------------

- Gross proceeds ~$100M from 1.45M shares, 31.9M pre-funded warrants, and 16.7M warrants at $3.00/share (warrant strike $4.50).
- Private placement led by BVF Partners LP; new investors include Venrock, Vivo Capital, Janus Henderson, Vestal Point, Velan Capital, ADAR1, Stonepine, Sphera Biotech.
- Net proceeds to complete Phase 3 LEVEL trial and initiate second Phase 3 trial of oral levosimendan; cash runway extended through end of 2027.
- Expected to close August 8, 2024; Leerink Partners lead placement agent, with Guggenheim, William Blair as joint agents; ROTH Capital financial advisor.
- Post-closing common shares outstanding expected to be approximately 3.4 million.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495424009988/0001654954-24-009988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495424009988/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-009988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer